US Bancorp’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

US Bancorp's RETA Position: Q3 2023 in Review

US Bancorp sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 8,875 shares — an estimated $905K sold.

US Bancorp first reported a position in RETA in Q3 2019 and held it in 16 quarters. The position peaked at $905K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

• US Bancorp reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
• US Bancorp sold 8,875 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $905K.
• US Bancorp first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2019 and held it in 16 quarters.
• US Bancorp's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $905K in Q2 2023.
• 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on US Bancorp's 13F filing for Q3 2023, filed 3 Nov 2023.